Previous 10 | Next 10 |
Exelixis ([[EXEL]] -3.2%) is trading ~3.1% lower in the post-market after announcing results from the metastatic castration-resistant prostate cancer ((CRPC)) cohort six of the COSMIC-021 study for cabozantinib (CABOMETYX) and atezolizumab combination in locally advanced/ metastatic soli...
Some healthcare stocks are especially intriguing to investors. Telehealth leader Teladoc Health (NYSE: TDOC) , biotech Exelixis (NASDAQ: EXEL) , and skin genomics testing pioneer DermTech (NASDAQ: DMTK) are three that certainly belong in the category. In this ...
The following slide deck was published by Exelixis, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Exelixis, Inc. 2021 Q1 - Results - Earnings Call Presentation
Ipsen (IPSEY) has exercised its option to collaborate with Exelixis (EXEL) in a pivotal trial for Cabometyx (cabozantinib) in patients with radioiodine-refractory differentiated thyroid cancer ((DTC)).Following the exercise of the option, Ipsen which already has an exclusive partner...
GlaxoSmithKline (NYSE: GSK) announced plans to sell the royalties it receives on sales of Exelixis ' (NASDAQ: EXEL) Cabometyx and Cometriq to Royalty Pharma (NASDAQ: RPRX) . In this video from Motley Fool Live , recorded on April 5 , Fool.com Contribu...
Image source: The Motley Fool. Exelixis Inc (NASDAQ: EXEL) Q1 2021 Earnings Call May 6, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript
Exelixis (EXEL) Q1 2021 Earnings Conference Call May 06, 2021, 17:00 PM ET Company Participants Susan Hubbard - Executive Vice President-Public Affairs and Investor Relations Mike Morrissey - President and Chief Executive Officer Chris Senner - Chief Financial Officer Peter Lamb - Chief Scien...
While Exelixis (EXEL) beat Q1 estimates on revenue, its net income narrowed significantly year-over-year.Revenue of $270.2M for the quarter grew 19.1% year-over-year.The company noted the sales increase was partially driven by uptake of the combination therapy of CABOMETYX (cabozantinib)...
Exelixis (EXEL): Q1 Non-GAAP EPS of $0.09; GAAP EPS of $0.00 misses by $0.03.Revenue of $270.23M (+19.1% Y/Y) beats by $3.79M.2021 Guidance: Total revenues: $1,150M - $1,250MNet product revenues: $950M - $1,050MPress Release For further details see: Exelixis EPS misses by $0.03, be...
- Total Revenues of $270.2 Million, Cabozantinib Franchise Revenues of $227.2 Million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2021 and provided an ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...